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Sorafenib is a small orally available multikinase inhibitor 
which is approved for the treatment of advanced renal 
cancer and hepatocellular carcinoma and is one of the first 
agents in molecular targeted therapy that was brought into 
clinical trials for metastatic melanoma patients. It blocks 
tumor proliferation by targeting the vascular endothelial 
growth factor receptors, platelet-derived growth factor 
receptors, RAF1, BRAF and probably other receptors 
involved in signal transduction in tumor cells (1). It is not 
exactly understood which targets of the above are the most 
relevant ones in the therapy of advanced melanoma.
In a double blind randomized phase II study sorafenib 
was investigated in combination with dacarbazine versus 
dacarbazine alone. In a dose of 400 mg twice daily in 101 
patients (2) there was a sign for improved progression free 
survival (PFS) and an improved response rate. However the 
differences were not significant. 
Hauschild et al. conducted a randomized placebo-
controlled phase III clinical trial (PRISM) comparing 
polychemotherapy with carboplatin and paclitaxel alone 
versus in combination with sorafenib in a patient population 
of 270 advanced melanoma patients in the second line 
setting (3). There was a response rate of 11% or 12% for the 
sorafenib group with very similar progression free survival 
of approximately 4.5 months. In a very recent issue of the 
Journal of Clinical Oncology, Flaherty et al. published the 
results of a phase III study with similar design as the PRISM 
in chemotherapy-naïve metastatic melanoma patients (4). 
In this study the combination carboplatin, paclitaxel plus 
placebo was compared to the two chemotherapeutic drugs 
in combination with sorafenib. There was a response rate 
of around 20% in both arms with a very similar progression 
free survival of 4.2 months for carboplatin-paclitaxel and 
4.9 months for carboplatin-paclitaxel and sorafenib with no 
impact of overall survival. 
There are several interesting conclusions that can be 
drawn from this data: 
(I) The response rate and the progression free survival 
is very similar for the aggressive polychemotherapy 
both in first and second line setting (3,4);
(II) The addition of sorafenib in unselected patient 
populations does not improve the response, nor the 
progression free survival.
There are some indications that sorafenib might 
provide a benefit in certain subpopulations of melanoma 
patients, such as in patients with high LDH levels or special 
melanoma subtypes, such as sinonasal or uveal melanomas. 
However there is currently no accepted biomarker which 
allows us to identify the patients that are more likely to 
respond to sorafenib.
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